85
Participants
Start Date
March 14, 2025
Primary Completion Date
October 3, 2028
Study Completion Date
October 3, 2028
IPN01195
IPN01195 will be administered at assigned dose level.
RECRUITING
Virginia Cancer Specialist- Fairfax, Fairfax
RECRUITING
Sarah Cannon Research Institute (SCRI) - Nashville, Nashville
RECRUITING
START Mid-West, Grand Rapids
RECRUITING
Mary Crowley Cancer Research Centers - Medical City Hospital - Dallas, Dallas
RECRUITING
START Mountan Region, West Valley City
NOT_YET_RECRUITING
Centre Léon Bérard - Lyon, Lyon
RECRUITING
Paris Saint-Louis, Paris
NOT_YET_RECRUITING
IGR-Villejuif, Villejuif
RECRUITING
Istituto Nazionale dei Tumori, Milan
RECRUITING
Istituto Nazionale Tumori IRCCS - Fondazione Pascale, Napoli
NOT_YET_RECRUITING
Val D'Hebron, Barcelona
RECRUITING
Hospital Universitario Quirónsalud Madrid, Madrid
NOT_YET_RECRUITING
M.D. Anderson Center Madrid, Madrid
Lead Sponsor
Ipsen
INDUSTRY